Biophytis – Sarconeos (BIO101)

Biophytis is developing a portfolio of programs that target biological resilience pathways that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Biophytis was granted IND approval in December 2019 from the FDA to initiate a Phase 1/2 clinical proof of concept trial (MYODA-INT) of an oral pediatric formulation of Sarconeos (BIO101), utilizing a ‘seamless’ clinical trial design with composite clinical endpoints. This trial is expected to begin early in 2023 with the aim of treating Duchenne’s Muscular Dystrophy.